$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How much is Jisandai (Bingtongsha) medical insurance policy and price and how to purchase it?
2026-02-01 22:25:32
Check Details
Can Jisandai (Bingtonsha) treat hepatitis C virus completely?
2026-02-01 22:25:32
Check Details
Is Jisandai (Bingtonsha) the best choice for hepatitis C treatment?
2026-02-01 22:25:32
Check Details
A comprehensive guide to the treatment of chronic hepatitis C with Jisandai (Bingtonsha)
2026-02-01 22:25:32
Check Details
Detailed explanation of the side effects of Jisandai (Bingtonsha) and information you need to know before using it
2026-02-01 22:25:32
Check Details
How to safely and effectively stop taking Mobotinib?
2026-02-01 22:25:32
Check Details
What factors affect the treatment cycle of Mobotinib?
2026-02-01 22:25:32
Check Details
Mobotinib (mobosetinib) Side Effects and Management Strategies
2026-02-01 22:25:32
Check Details
How to use EIKANCE (0.01% atropine sulfate eye drops) to slow down the progression of myopia in children
2026-02-01 22:25:32
Check Details
How does EIKANCE (atropine 0.01%) eye drops slow down myopia in children?
2026-02-01 22:25:32
Check Details
What kind of medicine is EIKANCE?
2026-02-01 22:25:32
Check Details
Are EIKANCE (atropine 0.01%) eye drops effective?
2026-02-01 22:25:32
Check Details
1
2
...
968
969
970
971
972
973
974
...
10223
10224
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tazemetostat Dosage Guide: Laos Generic vs. Original Tazverik Comparison
2
Tivozanib: A Next-Generation Highly Selective VEGFR-Targeted Therapy Explained
3
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
4
Avatrombopag Complete Guide: Efficacy, Indications, and TPO-RA Drug Comparisons
5
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
6
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
7
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
8
Elagolix Side Effects and Safety Guide
9
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
10
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
11
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
12
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA